Managing skin side effects from cancer immunotherapy
Official title: Project 2: I CARE (Immunotherapy Cutaneous Adverse events REsearch)
Funded at City College of New York · NIH-11194445 · Data updated 2026-11-12
This project looks at why some people on immune checkpoint inhibitors get inflammatory skin problems and how to spot and help those most likely to have worse outcomes.
Quick facts
| Grant type | NIH-funded research |
|---|---|
| Study type | NIH-funded research |
| Funding institution | City College of New York NIH-funded |
| Lab location | 1 site (New York, United States) |
| Project start | September 26, 2008 |
| Project end | August 31, 2029 |
| Funding year | 2025 |
| Award (this year) | $196,250 |
| NIH project number | 5U54CA132378-17 |
| Project ID | NIH-11194445 on NIH RePORTER |
Who could benefit from this research
✓Could help
People receiving immune checkpoint inhibitors for cancer, especially those who develop or are at risk for immune-related skin problems, are the most likely candidates.
✕Less likely to help
People not treated with immune checkpoint inhibitors or whose symptoms are unrelated to immune-related skin conditions would be unlikely to benefit directly.
What this research studies
From a patient's point of view, the team collects blood and skin samples and combines medical, genetic, immune, and social-support information to understand who gets severe skin immune side effects from cancer immunotherapy. They focus on skin reactions because skin is easy to sample and often comes before other organ problems. The project links biology (like immune cell and HLA markers) with measures of stress and socioeconomic resources to find patterns that predict poor recovery. The investigators plan to use modern data methods to identify high-risk patients and design supportive approaches to reduce harm, especially for underserved groups.
Why it matters
Potential benefit: If successful, this work could help prevent or lessen skin side effects from immunotherapy and keep more patients on their cancer treatments.
How similar studies have gone: Prior research has identified risk factors for immune-related adverse events, but trials testing ways to reduce their impact—particularly in underserved populations—are still limited.
Where this research is happening
-
City College of New York
New York, United States Active
Researchers
- Principal investigator: Vuong, Bao Q — City College of New York
- Study coordinator: Vuong, Bao Q
Related research
Other NIH-funded projects on the same topics.
-
Boosting immune response to fight cancer
This study is exploring a new way to help your immune system better fight cancer by tweaking certain cells in your body, and it aims to improve treatment for people with advanced cancer.
-
A center focused on immunotherapy for pediatric cancers.
This study is exploring new ways to use the body's immune system to fight childhood cancers, aiming to create better treatments for kids whose cancers haven't responded well to standard therapies.
-
Algorithms to find HLA-E neoantigens for cancer immunotherapy
Aims to develop computer methods to discover tumor-specific targets presented by HLA-E to guide new T cell therapies for cancer.
-
Immunotherapy for glioblastoma: advancing treatment and understanding
A patient-friendly summary of a grant exploring new immune-based treatments for glioblastoma to improve options for people affected by this brain cancer.
-
How CRISPR-based gene activation could shape immunotherapy responses in clear cell cancers
A research project at Stanford is using CRISPR-based gene activation to understand why some clear cell ovarian and kidney cancers respond to immunotherapy while others do not.
-
Hybrid biomaterial system to boost immunotherapy for rheumatoid arthritis
A new, patient-facing immunotherapy approach uses specialized particles to retrain the immune system to calm RA in adults.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.